Thanks bfw. I think there were a couple other bromodomain/BET inhibitor abstracts at ASCO too. I will look for these and post later.

From the Celgene abstract and dosing table, seems like they could not dose everyday with CC-90010 and had to do intermittent dosing schedule and had side effects consistent with many other previous pan-BET inhibitors. If I recall, ZEN-3694 was found to have minimal side effects at the effective dose and could be dosed every day. However, I might not be recalling this correctly and may be confusing the Phase 1 ZEN-3694 single agent dose finding trial with the ZEN-3694 combo trial with enzalutamide. 

BearDownAZ